These results suggest that despite their clinical phenotype, this subset of patients has a significantly higher autoantibody burden and supports recent data of a protective effect of anti-IFN-α antibodies in SLE [31]. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.